Catalyst

Slingshot members are tracking this event:

Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PFE

100%
VRX

100%
RVNC

100%
AGN

100%

Additional Information

Clinical Data Phase 2 Active Comparator, Double-Blinded, Placebo-Controlled, Multi-Center Trial of RT002 Injectable Botulinum Toxin Type A for the Treatment of Glabellar Lines - 6-month duration of effect is statistically significant compared to BOTOX® Cosmetic - - All dose levels of RT002 achieved highly statistically significant, investigator-reported efficacy compared to placebo at Week 4 - - All dose levels of RT002 appear to be safe and well tolerated -
http://investors.rev...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 29, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rt002, Botox, Dysport, Phase 2, Treatment Of Frown Lines, Glabellar Lines